EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Pharmaceutical Stocks To Watch Today - March 31st
Here's Why You Don't Bet Against This Dividend King
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 - Here's Why
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry
Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players
Pfizer (NYSE:PFE) Hits New 52-Week High - Should You Buy? - Daily Political
Is It Time To Reconsider Pfizer (PFE) After Diverging Valuation Narratives?
Pfizer (NYSE:PFE) Shares Up 2.6% - Time to Buy?
Announced in June, positive topline results from registratio
Pfizer's (PFE) Shares Up Since Jim Cramer Said "Pass"
Eli Lilly's (LLY) Shares Up Since Jim Cramer Said He Was a Long Term Believer
$1.59 Billion PD-1 Resistant Head and Neck Cancer Market Analysis Report 2026: Size, Growth, and Segmentation Insights to 2030
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline
Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million
Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate
Pfizer (PFE) - Among the 15 Large Cap Stocks with Highest Dividends
Prediction: Buying Pfizer Stock Today Could Set You Up for Life
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial
Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks
Pfizer (NYSE:PFE) Stock Price Down 2% - Here's What Happened
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Analysts
Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples
Pfizer Oncology Wins Raise Questions On Valuation Gap And Future Revenues
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program
Top Pharmaceutical Stocks To Watch Today - March 25th - Markets Daily
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
Exchange Traded Concepts LLC Sells 60,810 Shares of Pfizer Inc. $PFE - Stock Observer
Pfizer (NYSE:PFE) Trading Down 2% - Here's Why
Preliminary Results for the Year Ended 31 December 2025
Jim Cramer on Pfizer: "I Just Need to Know Their Product Flow Better"
Jim Cramer Broke Down 5 Stocks Including Pharma Plays for Rising Oil
Should Pfizer's (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
Is Pfizer's Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE?
Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
Income Investors Face a Hard Truth About Pfizer's Payout Safety
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate
Pfizer Inc. $PFE Stock Holdings Increased by Czech National Bank
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
Vaccine for Lyme disease one step closer to coming to market - CBS New York
Pfizer (NYSE:PFE) Shares Up 1.2% After Analyst Upgrade
Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
The Iran War Could Make Your Next MRI More Expensive
Pensionfund Sabic Makes New Investment in Pfizer Inc. $PFE - Markets Daily
Top Pharmaceutical Stocks To Watch Today - March 25th - Daily Political
Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Time to Buy? - Stock Observer
A Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
Doctors say Lyme disease vaccine trial results 'encouraging' with 70% efficacy shown - Yahoo News Canada
Doctors say Lyme disease vaccine trial results 'encouraging' with 70% efficacy shown - AOL
IP Group - Call Option on Pfizer's Anti-Obesity Program | Investing.com UK
Pfizer Inc. $PFE Shares Bought by SG Americas Securities LLC - Markets Daily
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook
Company Website: https://www.pfizer.com NEW YORK -- (Busin
Pfizer (NYSE:PFE) Price Target Raised to $36.00
Pfizer working for approval on new Lyme disease vaccine as expert says tick activity rising in New England
Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC
Park Place Capital Corp Trims Position in Pfizer Inc. $PFE
Organon: A High Cash Yield Hidden Behind Patent Fatigue | Investing.com Canada
Pfizer and Valneva's Lyme Disease Vaccine Demonstrates Over 70% Efficacy in Key Trial, ETPharma
Enhanced dynamic risk stratification of smoldering multiple myeloma
Pfizer working to get approval on new Lyme disease vaccine. Expert says tick activity rising in New England. - CBS Boston
Pfizer says Lyme disease vaccine is holding promise - CBS Boston
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story
Health Care Up, but Not by Much, Amid Cyclical Rotation - Health Care Roundup | Morningstar
Dow Jones Top Company Headlines at 3 PM ET: Danone to Buy Protein-Shake Maker Huel for $1.2 Billion | Toyota ... | Morningstar
Is Pfizer (PFE) Offering Value After Its Post Covid Portfolio Shift And Mixed Returns?
Valneva Shares Plunge 36% Over Lyme Vaccine Phase 3 Data
Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why - Markets Daily
Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial | Euronews
Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
Pfizer says long-awaited Lyme vaccine was effective in study
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l'essai de Phase 3 VALOR
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial | Morningstar
Goodman Financial Corp Purchases 137,772 Shares of Pfizer Inc. $PFE
2 Unpopular Stocks That Should Get More Attention and 1 We Avoid
Pfizer, Valneva post mixed results for Lyme disease vaccine | BioWorld
IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ...
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis
Tencent: The Premier Hunter of Medical IPOs
Tencent: Der Superjäger für medizinische Börsengänge
Pfizer Inc. $PFE Stock Holdings Increased by Park Avenue Securities LLC
Sound View Wealth Advisors Group LLC Has $1.43 Million Position in Pfizer Inc. $PFE - Daily Political
PFIZER news
Trump Announces 25% Tariffs on Automobiles, Pharmaceuticals, and Semiconductors
Week Ahead: US And Canada Labour Markets Are In Focus, BoE Rate Decision
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
